{"id":"NCT05134974","sponsor":"Ocuphire Pharma, Inc.","briefTitle":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)","officialTitle":"Randomized, Parallel Arm, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Healthy Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-18","primaryCompletion":"2022-03-18","completion":"2022-03-29","firstPosted":"2021-11-26","resultsPosted":"2023-08-01","lastUpdate":"2023-08-29"},"enrollment":368,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Mydriasis","Dilation"],"interventions":[{"type":"DRUG","name":"Phentolamine Ophthalmic Solution 0.75%","otherNames":["NyxolÂ®","Nyxol"]},{"type":"DRUG","name":"Phentolamine Ophthalmic Solution Vehicle","otherNames":[]}],"arms":[{"label":"Phentolamine Ophthalmic Solution 0.75%","type":"ACTIVE_COMPARATOR"},{"label":"Phentolamine Ophthalmic Solution Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this study are:\n\n* To evaluate the efficacy of Nyxol to expedite the reversal of pharmacologically-induced mydriasis across multiple mydriatic agents with an emphasis on phenylephrine\n* To evaluate the efficacy of Nyxol to return subjects to baseline accommodation after worsening (with cycloplegic agents tropicamide and Paremyd)\n* To evaluate the safety of Nyxol\n* To evaluate any additional benefits of the reversal of pharmacologically-induced mydriasis\n* To evaluate the systemic exposure of Nyxol on pharmacokinetic (PK) sampling","primaryOutcome":{"measure":"Percent of Subjects' Study Eyes With Pupil Diameter Returning to Baseline","timeFrame":"90 minutes","effectByArm":[{"arm":"Phentolamine Ophthalmic Solution 0.75%","deltaMin":142,"sd":null},{"arm":"Phentolamine Ophthalmic Solution Vehicle","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":15,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":244},"commonTop":["Conjunctival Hyperaemia","Instillation site erythema","Dysgeusia"]}}